Therefore, inhibition of MICA/B shedding may also promote CD8+ T‐cell‐driven immunity and enhance the therapeutic efficacy of T‐cell checkpoint blockers and serve as an alternative for cancer patients who are resistant to PD‐1/PD‐L1 antibodies. The gene discussed is CD8A; the disease is cancer.